Citadel Advisors LLC Acquires Shares of 66,329 NuCana PLC Sponsored ADR (NCNA)

Citadel Advisors LLC acquired a new position in shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 66,329 shares of the company’s stock, valued at approximately $1,218,000. Citadel Advisors LLC owned approximately 0.21% of NuCana as of its most recent filing with the Securities & Exchange Commission.

Separately, Sphera Funds Management LTD. purchased a new position in NuCana during the third quarter worth approximately $919,000. 22.27% of the stock is currently owned by institutional investors and hedge funds.

Shares of NuCana PLC Sponsored ADR (NASDAQ NCNA) opened at $11.60 on Friday. NuCana PLC Sponsored ADR has a one year low of $9.64 and a one year high of $19.95.

A number of brokerages recently commented on NCNA. Jefferies Group began coverage on NuCana in a research report on Monday, October 23rd. They set a “buy” rating and a $25.00 price objective on the stock. Citigroup began coverage on NuCana in a research report on Monday, October 23rd. They set a “buy” rating and a $23.00 price objective on the stock. William Blair began coverage on NuCana in a research report on Monday, October 23rd. They set an “outperform” rating on the stock. Finally, Cowen began coverage on NuCana in a research note on Monday, October 23rd. They set an “outperform” rating for the company.

ILLEGAL ACTIVITY WARNING: This story was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/12/08/citadel-advisors-llc-acquires-shares-of-66329-nucana-plc-sponsored-adr-ncna.html.

NuCana Company Profile

NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Receive News & Ratings for NuCana PLC Sponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana PLC Sponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply